171 related articles for article (PubMed ID: 33818626)
1. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers.
Abreu-Gomez J; Lim C; Cron GO; Krishna S; Sadoughi N; Schieda N
Abdom Radiol (NY); 2021 Sep; 46(9):4370-4380. PubMed ID: 33818626
[TBL] [Abstract][Full Text] [Related]
2. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
3. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
5. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
6. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
7. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
10. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
11. High-temporal resolution DCE-MRI improves assessment of intra- and peri-breast lesions categorized as BI-RADS 4.
Liu Y; Wang S; Qu J; Tang R; Wang C; Xiao F; Pang P; Sun Z; Xu M; Li J
BMC Med Imaging; 2023 Apr; 23(1):58. PubMed ID: 37076817
[TBL] [Abstract][Full Text] [Related]
12. Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection.
Ziayee F; Schimmöller L; Blondin D; Boschheidgen M; Wilms LM; Vach M; Arsov C; Albers P; Antoch G; Ullrich T
Eur J Radiol; 2022 Nov; 156():110520. PubMed ID: 36116141
[TBL] [Abstract][Full Text] [Related]
13. DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.
Sun H; Du F; Liu Y; Li Q; Liu X; Wang T
Front Oncol; 2022; 12():925186. PubMed ID: 36578948
[TBL] [Abstract][Full Text] [Related]
14. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
[TBL] [Abstract][Full Text] [Related]
15. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
[TBL] [Abstract][Full Text] [Related]
16. [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].
Yuan CW; Li R; Li ZH; Liu Y; Shan GZ; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):838-842. PubMed ID: 37807737
[TBL] [Abstract][Full Text] [Related]
17. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
18. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
19. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of integrated
Zeng Y; Leng X; Liao H; Jiang G; Chen P
Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]